natgillin/translations-raw huggingface dataset:
Increased left ventricular output and increased stroke volume
zvišan iztis iz levega prekata in zvišanim utripnim volumnom
increased level of alkaline phosphatase in the blood ,
zvišana raven alkalne fosfataze v krvi,
increased level of bilirubin, a substance produced by the liver
zvišana raven bilirubina, snovi, ki nastaja v jetrih
increased level of calcium in the blood,
zvišana raven kalcija v krvi,
increased level of calcium in the urine, nausea.
zvišana raven kalcija v urinu, slabost.
increased level of cholesterol in the blood, low levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles or confused),
zvišan nivi holesterola v krvi, nizka raven natrija v krvi (simptomi so slabost in slabo počutje z občutkom šibkosti mišic in zmedenostjo)
increased level of creatinine in the blood
zvišana raven kreatinina v krvi
Increased level of creatinine in the blood
zvišana raven kreatinina v krvi,
increased level of creatinine in the blood red skin (erythema).
zvišana raven kreatinina v krvi rdečina (eritem)
increased level of potassium in your blood and
zvišanje vrednosti kalija v krvi in
increased level of the serum protein known as lipase
zvišana raven serumske beljakovine, imenovane lipaza
increased level of uric acid in the blood,
zvišana raven sečne kisline v krvi,
increased levels of bilirubin in the blood (hyperbilirubinaemia)
zvišane ravni bilirubina v krvi (hiperbilirubinemija)
Increased levels of calcium in your blood.
povečanje koncentracije kalcija v vaši krvi.
increased levels of cholesterol and/or pancreatic amylase (a digestive enzyme) in the blood increased levels of liver enzymes in the blood
zvišane ravni holesterola in/ali pankreatične amilaze (prebavnega encima) v krvi zvišane ravni jetrnih encimov v krvi
Increased levels of circulating fats in your blood
zvišane ravni maščob v krvnem obtoku,
Increased levels of creatine kinase in the blood that may result in muscle pain and weakness
povišane ravni kreatin kinaze v krvi, ki lahko povzročijo bolečine in oslabelost mišic
Increased levels of glucose in your blood.
povečanje koncentracije glukoze v vaši krvi.
Increased levels of hepatic enzymes have been seen in healthy subjects and patients treated with anidulafungin.
Pri zdravih preiskovancih in bolnikih, zdravljenih z anidulafunginom, so ugotavljali zvišane ravni jetrnih encimov.
Increased levels of hepatobiliary parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT) and bilirubin have occurred in paediatric and adolescent patients, without any consistent pattern in the observations of values above the upper limit of normal.
Pri pediatričnih bolnikih in mladostnikih so se zvišale ravni hepatobiliarnih parametrov, kot so alanin- aminotransferaza (ALT), aspartat-aminotransferaza (AST), gama-glutamiltransferaza (GGT) in bilirubin, brez doslednega vzorca opažanja vrednosti nad zgornjo mejo normalne vrednosti.
increased levels of insulin, a hormone regulating blood sugar levels
povišana raven hormona inzulina, ki uravnava sladkor v krvi,
Increased levels of pro-inflammatory cytokines (e.g.
Zvišana raven vnetnih citokinov (npr.
Increased levels of serum phosphorus can lead to hard deposits in your body called calcification.
Povišane ravni fosforja v serumu lahko povzročijo trde depozite v telesu, ki se imenujejo kalcifikacija.
Increased levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur.
Lahko se pojavi povečano število majhnih krvnih celic (imenovanih ploščice), ki so normalno vključene v nastajanje krvnih strdkov.
increased levels of the enzyme (creatine kinase) in your blood
povečane ravni encima (kreatin kinaze) v krvi
Increased levels of the enzyme alkaline phosphatase in the blood (an indicator of organ malfunction or injury, particularly liver, pancreas, bone, thyroid gland, or gall bladder).
povišane ravni encima alkalne fosfataze v krvi (ki kažejo na nepravilno delovanje ali poškodbo organov, predvsem jeter, trebušne slinavke, kosti, ščitnice ali žolčnika)
increased levels of the hormone prolactin in your blood
če imate zvišano vrednost hormona prolaktina v krvi
Increased levels of the liver enzymes (aspartate aminotransferase and alanine aminotransferase) in blood tests.
povečanje vrednosti jetrnih (encimov aspartat-aminotransferaze in alanin-aminotransferaze) pri preiskavi krvi
Increased levels of the liver enzymes (aspartate aminotransferase and alanine aminotransferase) in blood tests.
povečanje vrednosti jetrnih encimov (aspartat-aminotransferaze in alanin-aminotransferaze) pri preiskavi krvi
increased levels of the serum proteins lipase or amylase.
zvišane ravni serumskih beljakovin lipaze ali amilaze,
increased levels of triglycerides (fats) in your blood
povečane ravni trigliceridov (maščob) v krvi
increased levels of white blood cell count, decreased levels of certain white blood cells (lymphopenia)
zvišanje števila belih krvnih celic, zmanjšanje števila določenih belih krvnih celic (limfopenija),
increased levels of “ketone bodies” in your urine or blood
povečane koncentracije “ketonskih teles” v urinu in krvi
increased levels of “ketone bodies” in your urine or blood
povišane ravni “ketonskih teles” v urinu ali krvi
increased levels of “ketone bodies” in your urine or blood
zvišana raven "ketonskih teles" v urinu ali krvi
increased levels of “ketone bodies” in your urine or blood
zvišana raven "ketonskih teles" v urinu ali krvi,
increased libido
povečan libido
Increased lipase* Increased amylase*
povečana koncentracija lipaze*, povečana koncentracija amilaze
Increased lipase, increased amylase
zvišanje vrednosti lipaze, zvišanje vrednosti amilaze
increased lipid values, appetite disorders;
zvišani lipidi, motnje apetita;
increased lipids in the blood elevated liver enzymes
povečani lipidi v krvi zvišani jetrni encimi
increased lipids in the blood; elevated liver enzymes.
povečani lipidi v krvi; zvišani jetrni encimi.
Increased Liver Aminotransferases (see section 4.4)
Zvišane vrednosti jetrnih aminotransferaz (glejte poglavje 4.4)
increased liver enzyme levels in the blood; abnormal kidney function test reaction related to the infusion of the medicine
zvišana raven jetrnih encimov v krvi, nenormalni izvidi preiskav delovanja ledvic reakcije, povezane z infundiranjem zdravila
Increased liver enzyme values (gamma-glutamyltransferase) in the blood as seen from blood tests
zlatenica (hiperbilirubinemija), povečane vrednosti jetrnih encimov (gama-glutamiltransferaze) v krvi, kar pokažejo krvne preiskave.
increased liver enzymes
povečane vrednosti jetrnih encimov;
Increased liver enzymes
povišane vrednosti jetrnih encimov
increased liver enzymes
zvišane vrednosti jetrnih encimov
increased liver enzymes
zvišanje jetrnih encimov
increased liver enzymes (shown in blood tests)
zvišane koncentracije jetrnih encimov (kar pokaže krvna preiskava)
increased liver enzymes (shown in blood tests)
zvišanje jetrnih encimov (pokaže se na preiskavah krvi),
Increased liver enzymes and bilirubin levels, liver disorders, hepatitis
povišane vrednosti jetrnih encimov in bilirubina, motnje jetrne funkcije, hepatitis;
Increased liver enzymes in the blood have been seen in some people receiving ivacaftor.
Pri nekaterih ljudeh, ki jemljejo ivakaftor, so opazili zvišane jetrne encime v krvi.
Increased liver enzymes in the blood have been seen in some people receiving ivacaftor.
Pri nekaterih ljudeh, ki so prejemali ivakaftor, so opazili zvišane jetrne encime v krvi.
increased liver enzymes in the blood increased triglycerides (fatty acids) in the blood
povišane vrednosti jetrnih encimov v krvi povišane vrednosti trigliceridov (maščobnih kislin) v krvi
increased liver enzymes in the blood increased trigycerides (fatty acids) in the blood
povišane vrednosti jetrnih encimov v krvi povišane vrednosti trigliceridov (maščobnih kislin) v krvi
Increased liver function tests
zvišani testi jetrne funkcije
Increased liver function tests
zvišanje jetrnih funkcijskih testov
increased liver transaminases in your blood
zvišane koncentracija jetrnih transaminaz v krvi
increased liver transaminases in your blood
zvišane koncentracije jetrnih aminotransferaz v krvi
increased liver transaminases in your blood
zvišane koncentracije jetrnih transaminaz v krvi
increased liver, renal and digestive enzymes
zvišana raven jetrnih, ledvičnih in prebavnih encimov
increased menstrual bleeding; flu like symptoms, chest pain, swelling of the feet.
močnejše menstruacijske krvavitve; simptomi podobni gripi, bolečine v prsih, otekanje stopal.
Increased menstrual flow,
močnejša menstruacija
Increased minimum inhibitory concentration (MIC) values have been found in some isolates of Histophilus somni and Actinobacillus pleuropneumoniae. .
Pri nekaterih izolatih Histophilus somni in Actinobacyllus pleuropneumoniae so bile ugotovljene povišane vrednosti minimalne inhibitorne koncentracije (MIC).
Increased monitoring for rifabutin- associated adverse reactions including neutropenia and uveitis is recommended.
Priporoča se povečano spremljanje neželenih učinkov rifabutina, vključno z nevtropenijo in uveitisom.
Increased mortality and morbidity were seen at all doses (1 mg/kg/day) in lactating females in mouse pre- and postnatal development studies.
V študijah pre- in postnatalnega razvoja so pri doječih samicah opažali večjo umrljivost in obolevnost pri vseh odmerkih ( 1 mg/kg/dan).
increased mucous, phlegm
povečanje izločanja sluzi,
increased mucus production, change in mucus colour increased cough or increased breathing difficulties
obilnejše nastajanje sluzi, spremenjeno barvo sluzi, močnejši kašelj ali več težav z dihanjem.
increased muscle stiffness
povečana okorelost mišic
Increased muscle stiffness
povečana togost mišic
Increased muscle stiffness
povečana togost mišic,
increased muscle stiffness and inability to stretch
povečana okorelost mišic in nezmožnost mišic, da se raztegnejo
increased muscle tension
zvečana napetost mišic
Increased muscle tension, difficulty with speech, difficulty with coordination, reduced sense of taste, altered sleep pattern
povečana mišična napetost, težave pri govoru, težave s koordinacijo, zmanjšana sposobnost okušanja, spremenjen vzorec spanja
increased muscle tone or tension (hypertonia)
povečan mišični tonus ali napetost (hipertonija)
Increased need for diabetes medicine, salt imbalance, potassium loss due to low carbon dioxide levels (a condition called metabolic alkalosis);
povečana potreba po zdravilih za sladkorno bolezen, neravnovesje soli, izguba kalija zaradi nizkih ravni ogljikovega dioksida (stanje, ki ga imenujemo presnovna alkaloza);
increased need to pass water
povečana potreba po mokrenju
increased need to urinate at night
pogosto uriniranje ponoči
Increased need to urinate at night
povečana potreba po uriniranju ponoči
increased need to urinate, or to urinate more frequently
večja potreba po odvajanju urina ali bolj pogostemu uriniranju
increased need to urinate, to urinate at night, or to urinate more frequently thirst (requiring excessive drinking of water)
večja potreba po odvajanju urina, nočnemu uriniranju ali bolj pogostem uriniranju žeja (zaradi katere morate piti zelo veliko vode)
Increased neutrophils
povečanje števila nevtrofilcev
Increased number of certain white blood cells (eosinophils).
zvečano število nekaterih belih krvnih celic (eozinofilcev).
increased number of red blood cells
povečano število rdečih krvničk
Increased number of serious cardiovascular events, mainly myocardial infarction, has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200 mg BID and 400 mg BID compared to placebo (see section 5.1).
V dolgotrajni, s placebom nadzorovani študiji, so odkrili povečano število nevarnih srčnožilnih dogodkov, v glavnem miokardni infarkt, pri osebah s sporadičnimi adenomatoznimi polipi, zdravljenih s celekoksibom, v odmerkih po 200 mg dvakrat na dan in 400 mg dvakrat na dan v primerjavi s placebom (glejte poglavje 5.1).
increased number of times of passing urine
zvečana pogostnost uriniranja
increased number of white blood cells (leucocytosis), itching (pruritus), skin inflammation (exfoliative dermatitis), rash.
povečano število belih krvnih celic (levkocitoza), srbečica (pruritus), vnetje kože (eksfoliativni dermatitis), izpuščaj.
increased number of white blood cells called monocytes
zvišanje števila belih krvnih celic, imenovanih monociti
increased or abnormal liver function test results
povišani ali nenormalni izvidi preiskav delovanja jeter
increased or abnormal liver function test results
povišani ali nenormalni izvidi preiskav delovanja jeter,
Increased or decreased amount of calcium or potassium
zvečanje ali zmanjšanje vrednosti kalcija ali kalija
increased or decreased appetite
povečan ali zmanjšan apetit
Increased or decreased appetite
zvečan ali zmanjšan apetit,
increased or decreased appetite, weight gain
povečan ali zmanjšan apetit, pridobivanje telesne mase
Increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention
povečano ali zmanjšano nastajanje urina (zaradi poškodbe ledvic), boleče odvajanje urina ali kri/proteini v urinu, zadrževanje tekočine
Increased or high blood pressure
zvišan ali visok krvni tlak
increased or irregular heart rate
povečan ali nereden srčni utrip
increased or reduced sense of touch or sensation, abnormal sensation such as prickling, tingling and itchiness
povečana ali zmanjšana občutljivost za dotik ali občutek, nenormalni občutki, kot so ščemenje, skelenje in srbenje
increased painful or burning urination,
pogostejše, boleče ali pekoče uriniranje,
increased pancreatic amylase
zvečana koncentracija pankreasne amilaze
increased pancreatic amylase2, vomiting1, 2, 3, diarrhoea1, 3, nausea1, 2, 3
zvišanje pankreasne amilaze2, bruhanje1, 2, 3, driska1, 3, navzea1, 2, 3
Increased plasma concentrations of
Astemizol in terfenadin lahko
Increased plasma concentrations of
lahko pričakuje zvečanje koncentracij
Increased plasma concentrations of amiodarone.
Večja koncentracija amiodarona v plazmi.
Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia.
Večja koncentracija derivatov ergot, ki povzroči akutno ergotsko toksičnost, vključno z vazospazmom in ishemijo.
Increased plasma concentrations of ergot derivatives leading to acute ergot toxicity, including vasospasm and ischaemia.
Zvišana koncentracija ergot- derivatov v plazmi s posledičnimi ergotskimi toksičnimi učinki, vključno z vazospazmom in ishemijo.
Increased plasma concentrations of oral midazolam and triazolam.
Večja koncentracija peroralnega midazolama in triazolama v plazmi.
Increased plasma concentrations of quetiapine may lead to coma (see sectin 4.3).
Zvečane plazemske koncentracije kvetiapina lahko povzročijo komo (glejte poglavje 4.3).
Increased plasma concentrations of tenofovir resulting from co-administration of tenofovir disoproxil fumarate, ledipasvir/sofosbuvir and atazanavir/ritonavir may increase adverse reactions related to tenofovir disoproxil fumarate, including renal disorders.
Povečane koncentracije tenofovirja v plazmi zaradi sočasne uporabe dizoproksiltenofovirijevega fumarata, ledipasvirja/sofosbuvirja in darunavirja/ritonavirja lahko povečajo neželene reakcije, povezane z dizoproksiltenofovirijevim fumaratom, vključno z ledvičnimi boleznimi.
Increased pressure in the brain (intracranial hypertension)
Povišan tlak v možganih (intrakranialna hipertenzija)
Increased pressure in the eye (glaucoma)
zvišan očesni tlak (glavkom)
increased pressure in the eye (glaucoma)
zvišan tlak v očesu (glavkom)
Increased pressure in the eye (glaucoma), lacrimation increased
zvišan očesni tlak (glavkom), povečano solzenje
Increased pressure in the eye (glaucoma).
povečan pritisk v očesu (glavkom)
increased pressure in the eye (glaucoma);
zvišan tlak v očesu (glavkom);
Increased pressure in the eye including glaucoma, choroid and retinal disorders (chorioretinopathy);
povišan tlak v očesu, vključno z glavkomom, motnje žilnice in mrežnice (horioretinopatija);
increased pressure inside the eye
zvišan tlak v očesu
increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding) kidney failure after a severe bleeding
povečan pritisk v mišicah nog in rok po krvavitvi, kar lahko povzroči bolečino, oteklost, spremenjeno občutljivost, odrevenelost ali paralizo (utesnitveni sindrom po krvavitvi) odpoved ledvic po hudi krvavitvi
increased production of saliva
povečano izločanje sline;
increased production of saliva;
močnejše izločanje sline,
Increased production of tears, conjunctivitis (redness and soreness of the surface of the eye), nosebleed
večje izločanje solz, konjunktivitis (pordelost in vnetje površine očesa), krvavitev iz nosu
Increased protein levels in urine
zvišane ravni beljakovin v urinu,
Increased prothrombin time (PT), increased partial thromboplastin time (PTT), and hypofibrinogenemia can occur in patients receiving Oncaspar.
Pri bolnikih, ki prejemajo zdravilo Oncaspar, se lahko pojavijo podaljšan protrombinski čas (PČ), podaljšan parcialni tromboplastinski čas (PTČ) in hipofibrinogenemija.
Increased pulse
zvišan srčni utrip
Increased rates of biopsy confirmed acute rejection (BCAR) have been observed with concomitant use of sirolimus with ACE inhibitors (see section 5.1).
Pri sočasni uporabi sirolimusa in zaviralcev ACE so opazili večji delež z biopsijo potrjene akutne zavrnitve (BCAR – Biopsy Confirmed Acute Rejection) (glejte poglavje 5.1).
Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed in patients treated with some myelotoxic chemotherapy regimens plus Avastin in comparison to chemotherapy alone.
Pri bolnikih, zdravljenih z nekaterimi mielotoksičnimi kemoterapevtskimi shemami in zdravilom Avastin, so v primerjavi s samo kemoterapijo opazili večji pojav hude nevtropenije, febrilne nevtropenije ali okužbe s hudo nevtropenijo ali brez nje (vključno s smrtnimi primeri).
Increased rates of severe neutropenia, febrile neutropenia, or infection with or without severe neutropenia (including some fatalities) have been observed mainly in patients treated with platinum- or taxane-based therapies in the treatment of NSCLC and mBC.
Opazili so večji pojav hude nevtropenije, febrilne nevtropenije ali okužbe s hudo nevtropenijo ali brez nje (vključno s smrtnimi primeri); to so večinoma opazili pri bolnikih, ki so prejemali zdravljenje na osnovi platine ali taksanov pri nedrobnoceličnem raku pljuč ter metastatskem raku dojk.
Increased reporting rates of convulsions (with or without fever) and hypotonic hyporesponsive episode (HHE) were observed with concomitant administration of Infanrix hexa and Prevenar 13 (see section 4.8).
Pri sočasni uporabi cepiva Infanrix hexa in cepiva Prevenar 13 so opazili povečano pogostnost poročanja o konvulzijah (z ali brez vročine) in hipotonično-hiporesponzivni epizodi (glejte poglavje 4.8).
Increased requirements for use of reliever medication (short-acting bronchodilators), or decreased response to reliever medication indicate deterioration of asthma control and patients should be reviewed by a physician.
Če bolnikova uporaba zdravil za olajšanje (kratkodelujočih bronhodilatatorjev) narašča, to kaže na slabšanje nadzorovanosti bolezni in bolnikovo stanje mora zdravnik znova oceniti.
Increased risk of blood clots in the eyes (retinal vein thrombosis)
Povečano tveganje krvnih strdkov v očeh (tromboza retinalnih ven)
Increased risk of blood clots in the eyes (retinal vein thrombosis).
povečano tveganje krvnih strdkov v očeh (tromboza retinalnih ven)
Increased risk of blood clots in the legs (deep vein thrombosis)
Povečano tveganje krvnih strdkov v nogah (globoka venska tromboza)
Increased risk of blood clots in the legs (deep vein thrombosis).
povečano tveganje krvnih strdkov v nogah (globoka venska tromboza)
Increased risk of blood clots in the lungs (pulmonary embolism)
Povečano tveganje krvnih strdkov v pljučih (pljučna embolija)
Increased risk of blood clots in the lungs (pulmonary embolism).
povečano tveganje krvnih strdkov v pljučih (pljučna embolija)
Increased risk of cardiac arrhythmias and torsades de pointes/wave burst arrhythmia in particular.
Povečano tveganje srčnih aritmij in zlasti pojava torsades de pointes/aritmije s porušitvijo valov.
increased risk of death when administered to achieve a haemoglobin concentration level of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
povečano tveganje za smrt, kadar so prejemali odmerke za doseganje ravni koncentracije hemoglobina 12 g/dl (7,5 mmol/l), pri bolnikih z aktivno maligno boleznijo, ki niso prejemali kemo- ali radioterapije.
increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.
povečala tveganje smrti pri bolnikih z aktivno maligno boleznijo, ki niso dobivali ne kemoterapije ne obsevanja, če je bila ciljna vrednost hemoglobina 120 g/l (7,5 mmol/l).
increased risk of death when administered to target a haemoglobin of 12 g/dl (7.5 mmol/l) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy.ESAs are not indicated for use in this patient population.
povečala tveganje smrti pri bolnikih z aktivno maligno boleznijo, ki niso dobivali ne kemoterapije ne obsevanja, če je bila ciljna vrednost hemoglobina 120 g/l (7,5 mmol/l).
Increased risk of dose-dependent adverse reactions such as rhabdomyolysis (decreased hepatic metabolism of cholesterol-lowering agent).
Povečano tveganje neželenih učinkov, ki so odvisni od odmerka, npr. rabdomioliza (zmanjšana jetrna presnova zdravil za znižanje ravni holesterola).
increased risk of getting a oestrogen-sensitive cancer (such as having a mother, sister or grandmother who has had breast cancer)
zvečano tveganje za razvoj od estrogenov občutljivega raka (npr. mater, sestra ali babica, ki je imela raka dojke);
increased risk of grade 3-4 hypertension (including hypertension and one case of essential hypertension) has been observed in patients receiving the ZALTRAP/FOLFIRI regimen.
Pri prejemnikih sheme ZALTRAP/FOLFIRI so zabeležili večje tveganje za hipertenzijo 3. do 4. stopnje (vključno s hipertenzijo in enim primerom esencialne hipertenzije.
Increased risk of haemorrhage
Povečano tveganje za krvavitev
Increased risk of side-effects (respiratory depression, sedation) due to higher plasma concentrations because of CYP3A4 inhibition by Kaletra
Povečano tveganje za neželene učinke (dihalna stiska, sedacija) zaradi večjih plazemskih koncentracij, ki jih povzroči zdravilo Kaletra z inhibicijo CYP3A4.
increased saliva (drooling)
povečano izločanje sline
Increased saliva production, heartburn, numb around mouth
močnejše slinjenje, zgaga, otrplost okrog ust
Increased saliva production, heartburn, numb around mouth.
močnejše slinjenje, zgaga, otrplost okrog ust
Increased saliva production, heartburn, numb around mouth.
Močnejše slinjenje, zgaga, otrplost okrog ust.
Increased score (Worsening)
Višji rezultat (poslabšanje)
increased sensation
povečana občutljivost
increased sensitivity of skin to sun
povečana občutljivost kože na sončno svetlobo
increased sensitivity of skin to the sun sugar in the urine.
povečana občutljivost kože na sončno svetlobo sladkor v urinu
increased sensitivity of sound, taste or touch or changes in smell
povečana občutljivost na zvok, okus ali dotik ali spremembe zaznavanja vonja,
increased sensitivity of sound, taste or touch or changes in smell
povečana občutljivost na zvok, okus ali dotik ali spremembe zaznavanja vonja;
increased sensitivity of the eyes or the skin to light
povečana občutljivost oči ali kože za svetlobo
increased sensitivity of the skin to sunlight decreased feeling or sensitivity, especially in the skin
večja občutljivost kože za svetlobo, zmanjšano zaznavanje ali občutljivost, zlasti na koži